Gastrointestinal Gene Therapy Biotech Company DNAlite Therapeutics Raises $1.5M

DNAlite Therapeutics, a San Francisco, CA-based gastrointestinal gene therapy biotech company, raised $1.5M in seed funding.

The round was led by Berkeley-based Berkeley Catalyst Fund with participation from University of California Berkeley, Blue Bear Ventures, SOSV, and the Baldota family alongside Chinese biopharma BrightGene and Silicon Valley-based SVE Capital.

The company intends to use the funds to continue development of gastrointestinal tract gene therapy treatments for patients who suffer from genetic intestinal diseases.

Founded by UC Berkeley graduates Mubhij Ahmad and Timothy Day in 2016, DNAlite leverages proprietary delivery platform technology to develop a gene therapy strategy to treat monogenetic gastrointestinal diseases by delivering a functional copy of the gene to patients’ gastrointestinal epithelium.



Join the discussion